Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'
- PMID: 33103782
- DOI: 10.1111/bjh.17110
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'
Comment on
-
Impact of immunosuppression on mortality in critically ill COVID-19 patients.Br J Haematol. 2020 Nov;191(3):394-395. doi: 10.1111/bjh.17108. Epub 2020 Oct 26. Br J Haematol. 2020. PMID: 33103761 No abstract available.
References
-
- Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day JW, Chavda SJ, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol. 2020. https://doi.org/10.1111/bjh.17027
-
- Mirouse A, Darmon M, Zafrani L, Lengline E, Azoulay E. Impact of immunosuppression on mortality in critically ill COVID-19 patients. Br J Haematol. 2020.
-
- Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38.
-
- Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907-18.
-
- Lee LYW, Cazier JB, Starkey T, Turnbull CD, Team UKCCMP, Kerr R, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919-26.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
